Correction to: Ansari et al., "Constitutive interferon-inducible protein 16-inflammasome activation during Epstein- Barr virus latency I, II, and III in B and epithelial cells" [Journal of Virology, 87, 15, (2013) (8606-8623)] doi: 10.1128/JVI.00805-13;Constitutive interferon-inducible protein 16-inflammasome activation during epstein-barr virus latency I, II, and III in B and epithelial cells

Journal of Virology

Volumn 87, Issue 15, 2013, Pages 8606-8623

  Ansari, Mairaj Ahmed ^a   Singh, Vivek Vikram ^a   Dutta, Sujoy ^a   Veettil, Mohanan Valiya ^a   Dutta, Dipanjan ^a   Chikoti, Leela ^a   Lu, Jie ^b   Everly, David ^a   Chandran, Bala ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS ASSOCIATED SPECK LIKE PROTEIN; CRYOPYRIN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ENOCED SMALL RNA 1; EPSTEIN BARR VIRUS ENOCED SMALL RNA 2; INFLAMMASOME; INTERFERON; INTERFERON INDUCIBLE PROTEIN 16; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33; PROTEIN AIM2; RAB27A PROTEIN; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EXOSOME; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAJI CELL; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS LATENCY;

EID: 84880617721     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01519-17     Document Type: Erratum

References (56)

1. Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, Aoki S, Minami M, Uozaki H, Fukayama M, Ohtomo K. 2009. Spectrum of Epstein-Barr virus-related diseases: a pictorial review. Jpn. J. Radiol. 27:4-19.
2. Savard M, Belanger C, Tardif M, Gourde P, Flamand L, Gosselin J.2000. Infection of primary human monocytes by Epstein-Barr virus. J.Virol. 74:2612-2619.
3. Gulley ML, Tang W. 2008. Laboratory assays for Epstein-Barr virusrelated disease. J. Mol. Diagn. 10:279-292.
4. Amon W, Farrell PJ. 2005. Reactivation of Epstein-Barr virus from latency.Rev. Med. Virol. 15:149-156.
5. Young LS, Arrand JR, Murray PG. 2007. EBV gene expression and regulation, p 461-489. In Arvin A, Campadelli-Fiume G, Mocarski E,Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
6. Munz C, Moormann A. 2008. Immune escape by Epstein-Barr virus associated malignancies. Semin. Cancer Biol. 18:381-387.
7. Thorley-Lawson DA, Duca KA, Shapiro M. 2008. Epstein-Barr virus: a paradigm for persistent infection-for real and in virtual reality. Trends Immunol. 29:195-201.
8. Hui-Yuen J, McAllister S, Koganti S, Hill E, Bhaduri-McIntosh S. 2011.Establishment of Epstein-Barr virus growth-transformed lymphoblastoid cell lines. J. Vis. Exp. 57:e3321.
9. Thorley-Lawson DA. 2001. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:75-82.
10. Miyauchi K, Urano E, Yoshiyama H, Komano J. 2011. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma. Cancer Sci. 102:1236-1241.
11. Khan G. 2006. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp. Hematol. 34:399-406.
12. Mogensen TH. 2009. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22:240-273.
13. Liew FY, Pitman NI, McInnes IB. 2010. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10:103-110.
14. Dinarello CA. 2010. IL-1: discoveries, controversies and future directions.Eur. J. Immunol. 40:599-606.
15. Martinon F, Mayor A, Tschopp J. 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27:229-265.
16. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ,Takeuchi O, Akira S. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6:981-988.
17. Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H,Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G. 2009.An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat. Immunol. 10:266-272.
18. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. 2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458:509-513.
19. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G,Caffrey DR, Latz E, Fitzgerald KA. 2009. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458:514-518.
20. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S,Sirois CM, Jin T, Latz E, Xiao TS, Fitzgerald KA, Paludan SR, Bowie AG. 2010. IFI16 is an innate immune sensor for intracellular DNA. Nat.Immunol. 11:997-1004.
21. Kerur N, Veettil MV, Sharma-Walia N, Bottero V, Sadagopan S, Otageri P, Chandran B. 2011. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi sarcoma-associated herpesvirus infection. Cell Host Microbe 9:363-375.
22. Singh VV, Kerur N, Bottero V, Dutta S, Chakraborty S, Ansari MA,Paudel N, Chikoti L, Chandran B. 2013. Kaposi's sarcoma-associated herpesvirus latency in endothelial and B cells activates gamma interferoninducible protein 16-mediated inflammasomes. J. Virol. 87:4417-4431.
23. Dawson MJ, Trapani JA. 1995. The interferon-inducible autoantigen, IFI 16: localization to the nucleolus and identification of a DNA-binding domain.Biochem. Biophys. Res. Commun. 214:152-162.
24. Johnstone RW, Wei W, Greenway A, Trapani JA. 2000. Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene 19:6033-6042.
25. Veeranki S, Choubey D. 2012. Interferon-inducible p200-family protein IFI16, an innate immune sensor for cytosolic and nuclear double-stranded DNA: regulation of subcellular localization. Mol. Immunol. 49:567-571.
26. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N,Whitney BM, Lee JC. 1999. Nasopharyngeal carcinoma cell line (C666-1)consistently harbouring Epstein-Barr virus. Int. J. Cancer 83:121-126.
27. Lu J, Verma SC, Cai Q, Saha A, Dzeng RK, Robertson ES. 2012. The RBP-J binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation. PLoS Pathog. 8:e1002479. doi:10.1371/journal.ppat.1002479.
28. Halder S, Murakami M, Verma SC, Kumar P, Yi F, Robertson ES. 2009.Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One 4:e7214. doi:10.1371/journal.pone.0007214.
29. Thery C, Amigorena S, Raposo G, Clayton A. 2006. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. Chapter 3:Unit 3.22. doi:10.1002/0471143030.cb0322s30.
30. Meckes DG, Jr, Raab-Traub N. 2011. Microvesicles and viral infection. J.Virol. 85:12844-12854.
31. Stenmark H. 2009. Rab GTPases as coordinators of vesicle traffic. Nat.Rev. Mol. Cell Biol. 10:513-525.
32. Canaan A, Haviv I, Urban AE, Schulz VP, Hartman S, Zhang Z, Palejev D, Deisseroth AB, Lacy J, Snyder M, Gerstein M, Weissman SM. 2009.EBNA1 regulates cellular gene expression by binding cellular promoters.Proc. Natl. Acad. Sci. U. S. A. 106:22421-22426.
33. Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M,Hannesschlager N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, Hartmann G, Hornung V, Ruland J.2010. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat. Immunol.11:63-69.
34. Chen LC, Wang LJ, Tsang NM, Ojcius DM, Chen CC, Ouyang CN,Hsueh C, Liang Y, Chang KP, Chang YS. 2012. Tumour inflammasomederived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol. Med.4:1276-1293.
35. Chen MR. 2011. Epstein-Barr virus, the immune system, and associated diseases. Front. Microbiol. 2:5. doi:10.3389/fmicb.2011.00005.
36. Jin T, Perry A, Jiang J, Smith P, Curry JA, Unterholzner L, Jiang Z,Horvath G, Rathinam VA, Johnstone RW, Hornung V, Latz E, Bowie AG, Fitzgerald KA, Xiao TS. 2012. Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity 36:561-571.
37. Brazda V, Coufal J, Liao JC, Arrowsmith CH. 2012. Preferential binding of IFI16 protein to cruciform structure and superhelical DNA. Biochem.Biophys. Res. Commun. 422:716-720
38. Zannis-Hadjopoulos M, Yahyaoui W, Callejo M. 2008. 14-3-3 cruciform-binding proteins as regulators of eukaryotic DNA replication.Trends Biochem. Sci. 33:44-50.
39. Jagelska EB, Brazda V, Pecinka P, Palecek E, Fojta M. 2008. DNA topology influences p53 sequence-specific DNA binding through structural transitions within the target sites. Biochem. J. 412:57-63.
40. Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D,McInnes IB, Hammerschmidt W, O'Neill LA, Masters SL. 2012. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J. Immunol. 189:3795-3799.
41. Li T, Diner BA, Chen J, Cristea IM. 2012. Acetylation modulates cellular distribution and DNA sensing ability of interferon-inducible protein IFI16. Proc. Natl. Acad. Sci. U. S. A. 109:10558-10563.
42. Smith VP, Alcami A. 2000. Expression of secreted cytokine and chemokine inhibitors by ectromelia virus. J. Virol. 74:8460-8471.
43. Gregory SM, Davis BK, West JA, Taxman DJ, Matsuzawa S, Reed JC,Ting JP, Damania B. 2011. Discovery of a viral NLR homolog that inhibits the inflammasome. Science 331:330-334.
44. Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, Salvesen GS,Pickup DJ. 1992. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 69:597-604.
45. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. 2002. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J. 21:954-965.
46. Costa S, Borgogna C, Mondini M, De Andrea M, Meroni PL, Berti E,Gariglio M, Landolfo S. 2011. Redistribution of the nuclear protein IFI16 into the cytoplasm of ultraviolet B-exposed keratinocytes as a mechanism of autoantigen processing. Br. J. Dermatol. 164:282-290.
47. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S. 2002.Indirect activation of naive CD4† T cells by dendritic cell-derived exosomes.Nat. Immunol. 3:1156-1162.
48. Aglipay JA, Lee SW, Okada S, Fujiuchi N, Ohtsuka T, Kwak JC, Wang Y, Johnstone RW, Deng C, Qin J, Ouchi T. 2003. A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway. Oncogene 22:8931-8938.
49. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R,Botrugno OA, Parazzoli D, Oldani A, Minucci S, Foiani M. 2011.HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471:74-79.
50. Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S, Jackson SP. 2010. Human HDAC1 and HDAC2 function in the DNA-damage response to promoteDNAnonhomologous end-joining. Nat. Struct. Mol.Biol. 17:1144-1151.
51. van de Berg PJ, Heutinck KM, Raabe R, Minnee RC, Young SL, van Donselaar-van der Pant KA, Bemelman FJ, van Lier RA, ten Berge IJ.2010. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J. Infect. Dis. 202:690-699.
52. Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O,Strupp M, Arbusow V, Brandt T. 2003. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am. J.Pathol. 163:2179-2184.
53. Sharma-Walia N, Paul AG, Bottero V, Sadagopan S, Veettil MV, Kerur N, Chandran B. 2010. Kaposi's sarcoma associated herpes virus (KSHV)induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog. 6:e1000777. doi:10.1371/journal.ppat.1000777.
54. Johnson KE, Chikoti L, Chandran B. 2013. Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes. J. Virol. 87:5005-5018.
55. Gariano GR, Dell'Oste V, Bronzini M, Gatti D, Luganini A, De Andrea M, Gribaudo G, Gariglio M, Landolfo S. 2012. The intracellular DNA sensor IFI16 gene acts as restriction factor for human cytomegalovirus replication. PLoS Pathog. 8:e1002498. doi:10.1371/journal.ppat.1002498.
56. Orzalli MH, DeLuca NA, Knipe DM. 2012. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc. Natl. Acad. Sci. U. S. A. 109:E3008 -E3017.